Meet the MedCity Media Team

And take 2 minutes to help us make better for you.

Every year, we ask you to tell us a little about yourself (anonymously) to help us create better, more relevant content and features for you. We consider every response and very much appreciate you taking the time to assist us.

Please click the button above to open a simple, multiple choice survey that should only take 2 minutes to complete.

Thank you,

The MedCity Media Team

Zetia cholesterol drug data delayed until 2014, Merck says

10:00 am by | 0 Comments

Merck & Co Inc said in a regulatory filing that it now expects data from a large heart safety study of its cholesterol drug Zetia to be available in 2014 instead of 2013.

The eagerly anticipated 18,000-patient trial called IMPROVE- IT was designed to demonstrate Zetia's ability to reduce heart attacks and strokes in heart patients after earlier studies and critics of the medicine called its efficacy and safety into question.

The so-called outcomes study is testing the effect of Zetia and Merck's older cholesterol drug Zocor, or simvastatin, against Zocor alone, and is designed to end once 5,250 clinical events, such as heart attacks, have been reported.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.